---

---

trial   tags : Clinical-trials-phase-i   

save search

---

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.1 -2.49% -2.55% 90K |

Health Technology

| -5.59% | O: -2.42% H: 0.0% C: 0.0%
allonk first candidate lupus cell trial therapy

---

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
MEIP | $3.38 2.11% 2.07% 12K |

Health Technology

| -14.51% | O: -1.08% H: 1.9% C: 0.78%
pharma update leukemia study

---

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
ATXS | $10.56 0.1% 0.09% 320K |

Manufacturing

| -26.64% | O: 10.71% H: 0.9% C: -11.94%
star-0215 positive trial therapeutics results

---

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Published: 2024-03-13 (Crawled : 13:00) - biospace.com/
ERNA | $2.15 0.46% 4.8K |

Information

| -11.48% | O: 4.1% H: 0.0% C: -11.81%
LCTX | $1.2 -6.98% 0.0% 1M |

Health Technology

| 4.03% | O: 1.61% H: 2.38% C: -3.97%
rg6501 opregen innovation cell therapy results study

---

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M |

Health Technology

| -5.75% | O: 0.15% H: 0.59% C: 0.37%
ARVN | $34.3 2.54% 2.48% 800K |

Health Technology

| -30.0% | O: -1.09% H: 5.61% C: 4.49%
first breast cancer trial therapeutics advanced

---

Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
KRBP | $2.3 -90.21% 15K |

Health Technology

| 53.33% | O: -6.67% H: 27.14% C: 26.43%
first lung favorable cancer cell biopharma trial results

---

Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
RNA | $23.04 -2.17% -2.21% 1.1M |

Health Technology

| 231.69% | O: 0.0% H: 10.7% C: 10.28%
positive

---

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K |

| 303.73% | O: 7.68% H: 0.06% C: -3.21%
urticaria study

---

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
RLYB | $1.68 -4.55% -4.76% 350K |

| -25.65% | O: 2.17% H: 3.74% C: -11.91%
rlyb212 antibody study

---

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Published: 2023-11-17 (Crawled : 11:00) - biospace.com/
PTCHF | $2.78 19.97% 560 |

n/a

| 30.52% | O: 0.0% H: 1.64% C: -2.82%
KRTX | $329.83 0.0% 1.9M |

Health Technology

| 95.62% | O: 1.79% H: 0.0% C: 0.0%
positive blood schizophrenia trial therapeutics results

---

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
Published: 2023-11-01 (Crawled : 12:00) - biospace.com/
SLN | $21.98 1.95% 1.91% 120K |

Health Technology

| 221.79% | O: 6.42% H: 29.45% C: 21.46%
disease positive topline therapeutics cardiovascular results study

---

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
Published: 2023-10-16 (Crawled : 12:00) - biospace.com/
NNVC | $1.175 1.29% 0.0% 13K |

Health Technology

| -4.13% | O: 0.0% H: 3.31% C: -3.31%
nv-387 active antiviral rsv trial

---

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
Published: 2023-10-13 (Crawled : 23:00) - biospace.com/
RPTX 4 | $3.025 -5.76% -6.12% 140K |

Health Technology

| -46.07% | O: -0.54% H: 2.33% C: -5.21%
positive trial therapeutics

---

GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Published: 2023-10-10 (Crawled : 12:30) - biospace.com/
SLS | $1.505 6.74% 6.31% 1.6M |

Health Technology

| -1.4% | O: 0.0% H: 10.48% C: -0.7%
gfh009 t-cell lymphomas trial

---

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Published: 2023-09-18 (Crawled : 12:00) - biospace.com/
NUVL | $62.97 -1.99% -2.03% 610K |

| 35.66% | O: -2.87% H: 1.28% C: -3.3%
nvl-655 symposium trial

---

Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
Published: 2023-09-14 (Crawled : 13:00) - biospace.com/
EWTX | $15.43 -1.41% -1.43% 530K |

Manufacturing

| 161.07% | O: 1.41% H: 4.49% C: 4.18%
edg-7500 candidate cardiac trial therapeutics

---

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-09-13 (Crawled : 13:00) - biospace.com/
RGLS | $2.22 -5.13% -5.41% 200K |

Health Technology

| 52.05% | O: 16.44% H: 0.0% C: -2.35%
rgls8429 disease kidney treatment trial therapeutics

---

Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients
Published: 2023-07-18 (Crawled : 14:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K |

Communications

| Email alert Add to watchlist
cld-101 hope city trial

---

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -13.66% | O: 0.02% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K |

Health Technology

| 25.42% | O: 0.05% H: 1.33% C: 0.38%
ALNY | News | $145.045 -0.19% -0.19% 400K |

Health Technology

| -26.35% | O: 5.53% H: 5.23% C: -2.49%
disease alzheimer’s positive results

---

Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2023-07-13 (Crawled : 14:00) - biospace.com/
MBRX | News | $4.59 7.24% 6.75% 50K |

Health Technology

| 640.38% | O: 6.47% H: 27.69% C: 10.57%
publication treatment leukemia trial

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---